Single-fraction radiosurgery outcomes for large vestibular schwannomas in the upfront or post-surgical setting: a systematic review and International Stereotactic Radiosurgery Society (ISRS) Practice Guidelines.
Facial
Gamma Knife
Hearing
Large
Radiosurgery
Vestibular schwannoma
Journal
Journal of neuro-oncology
ISSN: 1573-7373
Titre abrégé: J Neurooncol
Pays: United States
ID NLM: 8309335
Informations de publication
Date de publication:
Oct 2023
Oct 2023
Historique:
received:
29
05
2023
accepted:
17
09
2023
medline:
13
11
2023
pubmed:
16
10
2023
entrez:
16
10
2023
Statut:
ppublish
Résumé
To perform a systematic review of literature specific to single-fraction stereotactic radiosurgery (SRS) for large vestibular schwannomas (VS), maximum diameter ≥ 2.5 cm and/or classified as Koos Grade IV, and to present consensus recommendations on behalf of the International Stereotactic Radiosurgery Society (ISRS). The Medline and Embase databases were used to apply the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) approach. We considered eligible prospective and retrospective studies, written in the English language, reporting treatment outcomes for large VS; SRS for large post-operative tumors were analyzed in aggregate and separately. 19 of the 229 studies initially identified met the final inclusion criteria. Overall crude rate of tumor control was 89% (93.7% with no prior surgery vs 87.7% with prior surgery). Rates of salvage microsurgical resection, need for shunt, and additional SRS in all series versus those with no prior surgery were 9.6% vs 3.3%, 4.7% vs 6.4% and 1% vs 0.9%, respectively. Rates of facial palsy and hearing preservation in all series versus those with no prior surgery were 1.3% vs 3.4% and 34.2% vs 40.4%, respectively. Upfront SRS resulted in high rates of tumor control with acceptable rates of facial palsy and hearing preservation as compared to the results in those series including patients with prior surgery (level C evidence). Therefore, although large VS are considered classic indication for microsurgical resection, upfront SRS can be considered in selected patients and we recommend a prescribed marginal dose from 11 to 13 Gy (level C evidence).
Identifiants
pubmed: 37843727
doi: 10.1007/s11060-023-04455-8
pii: 10.1007/s11060-023-04455-8
pmc: PMC10638172
doi:
Types de publication
Systematic Review
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1-20Informations de copyright
© 2023. The Author(s).
Références
Int J Radiat Oncol Biol Phys. 2023 Jan 1;115(1):153-163
pubmed: 36075299
N Engl J Med. 2021 Apr 8;384(14):1335-1348
pubmed: 33826821
J Neurosurg. 2011 Mar;114(3):801-7
pubmed: 20799863
World Neurosurg. 2018 Jun;114:e1192-e1198
pubmed: 29614352
J Neurosurg. 2010 Dec;113 Suppl:112-21
pubmed: 21121793
J Neurosurg. 2016 Nov;125(5):1198-1203
pubmed: 26771854
World Neurosurg. 2016 Nov;95:487-501
pubmed: 27535636
Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):e503-9
pubmed: 21665381
Int J Radiat Oncol Biol Phys. 2001 Aug 1;50(5):1265-78
pubmed: 11483338
J Neurosurg. 1998 Mar;88(3):506-12
pubmed: 9488305
Acta Neurochir (Wien). 2017 Jun;159(6):1013-1021
pubmed: 28409393
Int J Radiat Oncol Biol Phys. 2003 Aug 1;56(5):1390-6
pubmed: 12873685
Lancet Oncol. 2019 Jan;20(1):159-164
pubmed: 30473468
Can J Neurol Sci. 2013 May;40(3):342-7
pubmed: 23603169
J Neurooncol. 2014 Jan;116(1):187-93
pubmed: 24142200
J Neurosurg. 2011 Nov;115(5):885-93
pubmed: 21838503
J Neurosurg. 2022 Jun 03;138(2):405-412
pubmed: 36303474
Acta Neurochir (Wien). 2019 Jul;161(7):1457-1465
pubmed: 31127373
J Neurosurg. 2021 Feb 12;135(4):1058-1066
pubmed: 33578383
Neurosurgery. 2009 Feb;64(2):289-96; discussion 296
pubmed: 19057423
Acta Neurochir (Wien). 2012 Sep;154(9):1679-84
pubmed: 22535199
J Neurosurg. 2005 Jan;102 Suppl:111-3
pubmed: 15662791
Stereotact Funct Neurosurg. 2020;98(2):85-94
pubmed: 32160612
Radiother Oncol. 2015 Mar;114(3):378-83
pubmed: 25702864
J Neurosurg. 2010 Apr;112(4):860-7
pubmed: 19663543
Neuro Endocrinol Lett. 2021 Jan;41(6):329-338
pubmed: 33714245
Clin Neurol Neurosurg. 2018 Mar;166:116-123
pubmed: 29414150
Asian J Neurosurg. 2019 Apr-Jun;14(2):487-490
pubmed: 31143267
J Clin Neurosci. 2016 Nov;33:239-241
pubmed: 27460514
J Clin Epidemiol. 2009 Oct;62(10):e1-34
pubmed: 19631507
J Neurosurg. 2016 Dec;125(Suppl 1):73-82
pubmed: 27903185
J Neurosurg. 2018 May;128(5):1380-1387
pubmed: 28707997
J Neurooncol. 2021 Jan;151(2):145-156
pubmed: 33415658
J Radiosurg SBRT. 2020;7(1):11-17
pubmed: 32802574
J Neurosurg. 2013 Aug;119(2):463-71
pubmed: 23706053
J Neurosurg. 2007 Oct;107(4):733-9
pubmed: 17937216
Neurosurgery. 2017 Sep 1;81(3):490-497
pubmed: 28368501
Neurosurgery. 2016 Apr;78(4):521-30
pubmed: 26606668
J Neurosurg. 2010 Dec;113 Suppl:105-11
pubmed: 21121792
Int J Radiat Oncol Biol Phys. 2011 Aug 1;80(5):1485-91
pubmed: 20708852
J Neurooncol. 2022 Aug;159(1):201-209
pubmed: 35729368
J Neurosurg. 2012 Mar;116(3):598-604
pubmed: 22175724
World Neurosurg. 2016 Sep;93:398-409
pubmed: 27368508
J Radiosurg SBRT. 2017;5(1):5-24
pubmed: 29296459
J Neurosurg. 2011 Nov;115(5):875-84
pubmed: 21838510